Dannon P N, Iancu I, Hirschmann S, Ross P, Dolberg O T, Grunhaus L
Chaim Sheba Medical Center, Psychiatry Division, Tel Hashomer, Israel.
J ECT. 1998 Dec;14(4):245-50.
Labetalol, a combined alpha- and beta-adrenergic blocker is often used to attenuate the transient increases in heart rate and blood pressure that accompany electroconvulsive therapy (ECT). It has been suggested that labetalol should not be administered during ECT without the protection provided by anticholinergic medications, because of its potential severe bradycardic effects. We present our experience with 32 patients from all age groups who received labetalol without anticholinergic treatment during ECT. None of the patients demonstrated adverse bradycardic effects. We conclude that administration of labetalol during ECT does not routinely require premedication with anticholinergic drugs and does not lengthen asystole.
拉贝洛尔是一种α和β肾上腺素能联合阻滞剂，常用于减轻电休克治疗（ECT）时伴随的心率和血压短暂升高。有人提出，由于拉贝洛尔有潜在的严重心动过缓作用，在ECT期间若没有抗胆碱能药物的保护则不应使用。我们介绍了32例各年龄段患者在ECT期间接受拉贝洛尔治疗而未进行抗胆碱能治疗的经验。所有患者均未出现不良心动过缓效应。我们得出结论，在ECT期间使用拉贝洛尔通常不需要预先使用抗胆碱能药物，也不会延长心搏停止时间。
